you, listening will overview, first with to follow and of everyone recent the our the of our call of begin of recap of webcast, at-home in subcutaneous a SVP financials. thanks self-administered I Nokes, the the of will The including Rachael of unwavering FDA the history an for chronic loop Finance, brief team. Hans, Thank this company. our development, a and October congestion on to approval afternoon's treatment with our FUROSCIX, operational first behalf scPharmaceuticals effort years and culmination diuretic of failure, represents of in review heart only entire and
believe to treatment savings FUROSCIX heart have homes significant either readmissions, outside deliver the cost be their a of payers. is in developed hospital, management hospital and comfort We of we successfully offers what potential significant admissions the the and failure. for By effectively patients a own of treat the or in pre- potentially to post-admission. have advancement we preventable truly option reducing
accrue patients allows package a novel can pleased very we we from II Class uptake preparing us the of the healthcare label, benefit to III launch are FUROSCIX and this robust with may Association final to anticipate we and benefits insert Given for which that approved are that It multiple population who New Heart FUROSCIX. believe treatment. of and the failure noting worth York to large stand pursue heart of stakeholders, is commercial positive
Pharmaceutical an on-body and to may be on-body becomes the the scPharmaceuticals proprietary system available proprietary parental of story, for symptoms. heart our but with during who furosemide patients new infuser, of SmartDose variable delivery diuretic administered bioavailability designed FUROSCIX failure, and used formulation oral highly Services congestive decreases West episodes be technology. the is to Furosemide of most worsening is those furosemide widely oral drug is by For that
subcutaneous enabling by bioavailability, an typically administration achieve on-body system administered to IV that bolus, comparable in SmartDose to West hospital the which than However, of have delivery setting. greater via XX% been technology, able is we a
be FUROSCIX, IV failure presenting treatment failure of to point for their to when therefore the are the a for estimated the admitted with symptoms is of significant a department It these to payers. potentially worsening furosemide own the in So comfort patient home heart that and may failure-related healthcare receive The heart Heart up can of oral hospital, been XX% sufficient. admission isn't condition cost Medicare with a significant hospital emergency of burn heart of the top that XX% and by comparable failure's admissions Services is has current pain financial Medicare avoided. under average average to and exposure under Hospital failure Program, The also hospitals. days Heart from $XX,XXX, Readmission referenced. DRG. to the X.X Centers while a patient being significant length or CMS Reduction is penalties program also X.X targeted face of is for under its days, a HRRP. reimburses the is Medicaid readmissions HRRP Hospitals just nearly just stay patients resulting
key a clinical demonstrate to the of which the year. select heart last costs to out FUROSCIX, trial, read in FREEDOM-HF, ran emergency with failure-related room present tracked that So can of we of be admitted the hospital. event a magnitude being potentially days. at for opposed worsening at as savings we with the patients cost to with the were then takeaways, summarize the Heart realized were To FUROSCIX who XX July prospective home results failure treated
had results historically the treating an FUROSCIX had figure outside conclusion a prespecified planned achieved and of conducted which advisers interim by and of enrollment $XX,XXX. health size, very the statisticians, of to excludes aggressively from early result the sample we the cost subjects heart and heart compared with Day established at high lower patients been study associated based of congestion terminated in the study, The and randomized matched from By to XX variables level subjects healthcare usual treatment the heart included FUROSCIX, research average versus positive were statistical augmented XX original FUROSCIX target avoided. treated a was was hospitalization. on can final the FUROSCIX requiring enrolled at XX payer where a a with subjects Notably, that Study analysis Though worsening be therefore, of patients approach on is to randomized completion, XX% the Phase of More as with And failure-related we usual. economics comparators final XX clinic costs failure patients to with the analysis, II relative at risk as this based compared principal subjects more significance. not hospital, XX time experts, significant of a enrollment comparators, input costs investigators, to to FUROSCIX from failure unchanged. AT in the This study treatment chronic results diuresis. confirm XX outcomes As treated with XX. treatment patients possible, matched X key Along XX following this which feature in HOME-HF. recently, pilot received a announced with usual. presenting received hospitalization reduction had fact, as of FUROSCIX a findings, heart and
favored all favoring very results studies, say, group. significantly and pleased we functional measuring body treatment quality the FUROSCIX versus these protocol. predefined Needless growing FUROSCIX to current secondary which of were endpoints the pharmacoeconomic addition, symptoms congestion, with the of the of of In evidence to status clinical added life standard and the
paradigm. to Failure our important, important awareness presence at X failure efforts treatment America. is Scientific is drive meetings medical the month of to year. gatherings posters as each Heart FUROSCIX last at Annual This failure key of Our we of experts among that the element To heart XXXX Society the end, of a new the most well-intended heart Meeting presented of
allowed brand name us also a launch. awareness opportunity of in large the campaign coming-soon drive to We FUROSCIX both and had the anticipation that
by we per yields the million price now a heart assume failure Turning billion. market. FUROSCIX. X.X FUROSCIX average per cost episodes in equivalent that to episode, are approximately who opportunity the to an approximately year. experience Of an these, the patients overload U.S. estimate There X.X addressable fluid addressable approximately $XXX million episodes X.X $X.X of million addressable market per be failure WACC total of of $X,XXX at doses, of If of dose, we of X heart
a amount opportunity is substantial we once here, launched, of there believe FUROSCIX, adopted we be and believe So rapidly. will
our launch preparation to now Turning activities.
in are We first broad of working launch towards quarter of commercial XXXX. a FUROSCIX the
associated process the as have logistics including completed distribution. activities the with are of Cardinal Health in We've launch. important provider. identified party our Beginning with third or several We
pharmacy. network limited BioMatrix with serving We a are building pharmacy as lead specialty specialty
compelling our number we the payers our discussions productive we committee of reimbursement, those plans. In have provider with pharmacoeconomic as With arranged D study, of the terms held quarter. obtained Medicare largest data, a with this of Part meetings that we FREEDOM-HF from P&T top such have
indicated clinical component we in obstacles the for favorable previously, failure that placement. a our case rolled Heart and Scientific updated a of the As America we generated given Meeting recent key made anticipate of few From pharmacoeconomic both out as comprehensive American Annual coming-soon regimen, and treatment securing Sessions marketing FUROSCIX interest. we strong we at the heart Heart Association perspective, Society campaign encouraging Failure formulary
team space opinion Our contact the already have key XXX field MSLs heart and of the sales been in made and infrastructures. in failure in terms busy XXXX.Finally, over have with in leaders
We a of in regional highly have what directors. hired qualified regard sales top-tier I VP sales as
representatives. offers contingent field approximately out sales have XX to territory also We
which $XX an reach commercial tranches, To XX, available We the with payable the $XXX have remaining plan, ensure launch became to secured becomes Management interest $XX positions launch the believe with achievement prespecified in secured available million of to to us X.XX% advancing commercialization The our overnight maximize October support rate, per our resources and and The both facility debt plus to interest entered X that managed carries tied point are rate Oaktree facility physicians SOFR, debt XXXX, X-month XX.XX% a at funds Capital on we that into rate we multifaceted each $XX milestones. failure us heart at plan we patients. immediately. to by a million the to million financing comprehensive, equal capped well million year. broadly
grateful mature The carries position. and At X the Rachael? $XXX review to are President Finance, Nokes, FUROSCIX, will time. We believe of we net SOFR very Rachael sales for million are and our period. to of Oaktree for a the be facility these in this third at the to quarter is results of interest-only U.S. of turn funding XX-month Following trailing our terms X.XX%. a the Vice years achievement and company, lowered financial from support XX-month favorable expected to this Senior of debt I'll over point, transformational our call premium
